Cellectis S.A [NASDAQ: CLLS] disclosed Friday that it has finalized the sales of nearly $47 million of ADS in accordance with the ATM program of the firm created on March 29, 2021. The sales representative of the firm is Jefferies LLC. The firm has revealed that each ADS signifies the ordinary share of the firm.
Shares of Cellectis soared 4.12% at $20.24 during the trading session of Thursday. In the past 52-weeks of a trading session, the shares of the firm fluctuated between the low range of $9.15 and a high range of $34.71. Its shares moved up 121.20% and moved down -41.69% from its 52-week low and high, respectively. CLLS has recorded a market cap of $837.94 million at the time of writing.
Cellectis S.A declared that a total of 2,415,630 new ADSs and the same number of original new ordinary shares have been granted to the current and new shareholders at an at-the-market price of $19.50 per new ADS. Furthermore, the firm has clarified that the delivery and adjustment of new ordinary shares will be scheduled to take place on April 12, 2021.
Moreover, shares will be accepted for trading on the market of Euronext Growth and the released ADSs will trade on Nasdaq. A shelf registration declaration on Form F-3 regarding securities of CLLS was submitted with the SEC and became valid upon submission on June 2, 2020.